Navigation Links
ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
Date:8/31/2011

EXTON, Pa., Aug. 31, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William C. Roberts, ViroPharma's Vice President of Corporate Communications, will present at the Stifel Nicolaus 2011 Healthcare Conference at 1:30 P.M. ET on Wednesday, September 7, 2011.  The conference is being held in Boston.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
2. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
3. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
4. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
5. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
6. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
7. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
8. ViroPharma to Participate In Three May Healthcare Investor Conferences
9. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
10. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
11. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
(Date:1/18/2017)... , Jan. 18, 2017  EnteroMedics Inc. (NASDAQ: ... devices using neuroblocking technology to treat obesity, metabolic ... pricing of an underwritten public offering of units ... deducting underwriting discounts and commissions and offering expenses ... comprised of Class A Units, priced at a ...
(Date:1/18/2017)... Jan. 18, 2017  Adaptive Sound Technologies, Inc. (ASTI), the ... partnership with Hyatt Place Nashville/Downtown to deliver the best ... sleep therapy machines in over two hundred of its ... important parts of having a great stay is sleeping ... Hyatt Place Nashville/Downtown. "We,re pleased to be able to ...
Breaking Medicine Technology:
(Date:1/18/2017)... Fresno, CA (PRWEB) , ... January 18, 2017 ... ... is pleased to announce that their Vice President of Franchise Development, Paula Turner ... , This award-winning business program, which features the insights of top business leaders ...
(Date:1/18/2017)... ... ... At Hallmark Nameplate, their commitment to quality is what sets them apart. The ... certification is another way they are making constant strides to provide all customers with ... The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and will allow ...
(Date:1/18/2017)... ... 18, 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), ... for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. ... through thought leader interaction in, live video and interactive digital platforms. , In ...
(Date:1/18/2017)... Hills, CA (PRWEB) , ... January 18, 2017 ... ... of dental problems ranging from gum disease to enamel erosion, and those dental ... the Massachusetts Department of Public Health, many pregnant women are failing to get ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Anesthesia Progress ... for dentists to choose the best drug option for each patient. Dentists have several ... and better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan ...
Breaking Medicine News(10 mins):